Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor

Joan R. Tymon-Rosario, Paola Manara, Diego D. Manavella, Stefania Bellone, Tobias Max Philipp Hartwich, Justin Harold, Yang Yang-Hartwich, Margherita Zipponi, Jungmin Choi, Kyungjo Jeong, Levent Mutlu, Kevin Yang, Gary Altwerger, Gulden Menderes, Elena Ratner, Gloria S. Huang, Mitchell Clark, Vaagn Andikyan, Masoud Azodi, Peter E. SchwartzLudmil B. Alexandrov, Alessandro D. Santin

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor'. Together they form a unique fingerprint.

Medicine & Life Sciences